Zimmer Biomet to Present at the 27th Annual Barclays Healthcare Conference: A Strategic Opportunity for Growth

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, has announced that members of its management team will be presenting at the 27th Annual Barclays Healthcare Conference on Thursday, March 13, 2025, at 9:30 a.m. ET. This presentation provides an excellent opportunity for the company to showcase its innovative products, strategic initiatives, and financial performance to investors and analysts.



Zimmer Biomet's presentation comes on the heels of its fourth quarter and full-year 2024 earnings report, which demonstrated strong financial performance. The company reported fourth quarter net sales of $2.023 billion, an increase of 4.3% over the prior year period, and an increase of 4.9% on a constant currency basis. Full-year net sales were $7.679 billion, an increase of 3.8% over the prior year, and an increase of 4.8% on a constant currency basis. Diluted earnings per share were $1.20 for the fourth quarter and $4.43 for the full year, while adjusted diluted earnings per share were $2.31 and $8.00, respectively.



During the presentation, Zimmer Biomet is expected to highlight its recent acquisition of Paragon 28, a leading medical device company focused exclusively on the foot and ankle orthopedic segment. This acquisition is a strategic move that aligns with Zimmer Biomet's commitment to diversifying its portfolio outside of core orthopedics and investing in higher growth end-markets. The acquisition is expected to immediately accelerate Zimmer Biomet's revenue growth and be accretive to adjusted EPS within 24 months of deal close.

Zimmer Biomet is also likely to discuss its innovative product portfolio, including the U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) for the Oxford® Cementless Partial Knee, the FDA 510(k) clearance for the OsseoFit™ Stemless Shoulder System, and the CE Mark Certification for the Persona® Revision Knee System. These products demonstrate the company's commitment to bringing innovative solutions to market that address areas of unmet need in the orthopedic segment.



In addition, Zimmer Biomet may provide an update on its financial guidance for the full year 2025, as well as its long-term growth prospects. The company's strong financial performance, combined with its strategic initiatives and innovative product portfolio, positions it well for continued growth and success in the medical technology sector.



In conclusion, Zimmer Biomet's presentation at the 27th Annual Barclays Healthcare Conference is an important opportunity for the company to showcase its strategic initiatives, innovative product portfolio, and strong financial performance. The presentation is expected to provide valuable insights into the company's growth prospects and its commitment to investing in higher growth end-markets. Investors and analysts should pay close attention to this presentation, as it may provide valuable information about the company's future direction and potential investment opportunities.

Word count: 598